The new tradipitant GLP-1 study reported less vomiting after semaglutide. Tradipitant blocks a vomiting signal; semaglutide mimics GLP-1, a gut hormone involved in appetite. The catch is how it was tested: participants started with a dose much higher than the usual starting dose. That makes this encouraging news about a possible additional treatment, with an important limit on what it says about everyday care.
What the tradipitant GLP-1 study found
As of October 29, 2026, the day this article was written, Vanda's October 27 announcement reports positive results from Study 3601. This phase 3 trial, a later-stage human study, compared tradipitant with placebo, an inactive treatment.
Everyone in the study received semaglutide. About 4 in 10 people who also took tradipitant vomited, compared with about 6 in 10 who took a placebo pill instead:
| Outcome | Tradipitant | Placebo |
|---|---|---|
| Any vomiting | 43.0% (61/142) | 58.5% (96/164) |
| Vomiting with severe nausea | 33.1% | 50.6% |
| Extreme vomiting: >10 total episodes | 2.8% | 14.6% |
The main comparison had p=0.006, a statistical measure of evidence against no difference. It does not tell us how much benefit an individual would feel.
The extreme-vomiting analysis was post hoc, meaning it was chosen after the study rather than specified in advance. It deserves less weight than the main result. Almost all vomiting occurred by Day 2, peaking on Day 1. Vanda reported no new safety signals, without a detailed side-effect table.
The main outcome was whether someone vomited at all. It was not proof that every participant felt comfortable, ate normally, or stayed on weight treatment longer. Those are separate questions that matter in daily life.
Why these aren't everyday Wegovy vomiting rates
Participants received one 1 mg semaglutide dose without gradual titration, the step-by-step increase used to help the body adjust. This challenge model deliberately created conditions likely to provoke vomiting. Vanda says a pooled analysis of its phase 2 and phase 3 data found the effect held across the semaglutide levels it observed, and argues that supports applying it to usual dosing. The release does not show that analysis's data, and it reports no study during gradual dose increases.
Both the Wegovy prescribing information, marked “Revised: 6/2026,” and the Ozempic prescribing information, marked “Revised: 5/2026,” start their injections at 0.25 mg weekly. Those are label facts, not a personal dosing plan.
Their section 6 tables provide a more useful reference for treatment with gradual increases:
| Adult trial group | Nausea | Vomiting | Corresponding placebo: nausea / vomiting |
|---|---|---|---|
| Wegovy 2.4 mg, weight-management trials | 44% | 24% | 16% / 6% |
| Ozempic 0.5 mg, diabetes trials | 15.8% | 5% | 6.1% / 2.3% |
| Ozempic 1 mg, diabetes trials | 20.3% | 9.2% | 6.1% / 2.3% |
These are different populations and follow-up periods. They cannot rank the brands or measure tradipitant's benefit during ordinary treatment. They do show why the new study's high vomiting rate should not be read as a forecast for someone starting semaglutide.
A pooled STEP 1–3 analysis by Wharton and colleagues, in Diabetes, Obesity and Metabolism in 2022, found gut side effects clustered around dose increases. It also found weight loss was largely independent of those symptoms. Feeling sick is not the measure of whether treatment is helping. Our guide to how long GLP-1 nausea lasts covers the timing separately.
What this means for semaglutide and tirzepatide
A medicine that makes treatment easier to tolerate would answer a real need. But a short prevention experiment cannot establish whether adding another medicine helps people continue treatment for months.
The registered study describes adults without diabetes or serious chronic disease. That matters because people prescribed semaglutide often have other conditions: Ozempic is prescribed for type 2 diabetes, which the study excluded, and in Wegovy's weight-management trials 42% of participants had high blood pressure and 19% had type 2 diabetes. A result in that selected group leaves questions about those patients.
Tirzepatide is another weight-management medicine with a GLP-1 component, meaning it acts on the same gut-hormone signal. Study 3601 tested semaglutide. Its results do not establish the same benefit with tirzepatide or settle which weight treatment suits a particular person.
NEREUS already has a different indication
Tradipitant, branded NEREUS, is an oral NK-1 receptor antagonist: it blocks a chemical signal involved in vomiting. Its current label, “Revised: 9/2026,” covers prevention of vomiting caused by motion in adults. It does not cover GLP-1-related nausea or vomiting.
The earlier Motion Syros trial, published in Frontiers in Neurology in 2025, studied 365 adults with a history of motion sickness on boat trips. Vomiting was less common with tradipitant, but nausea measured alone was not significantly different from placebo. That distinction matters: preventing vomiting and relieving nausea are related goals, not interchangeable ones.
An October 15, 2026 review in Annals of Pharmacotherapy pooled three motion-sickness trials with 808 adults: vomiting was less common with tradipitant, and fatigue was reported more often than with placebo. None of those trials involved a GLP-1 medicine.
The NEREUS label lists sleepiness, headache, and fatigue, and warns about impaired driving. Some other medicines can raise tradipitant levels in the blood. Adding it would therefore require its own medication review, even for someone already receiving GLP-1 treatment.
What prescribers can consider now
Gradual dose increases remain part of the semaglutide labels. Wegovy's label says that if a dose is not tolerated during the increases, clinicians can consider delaying the next increase for 4 weeks. The prescriber sets the actual dose and timing.
A multidisciplinary expert consensus published in the Journal of Clinical Medicine describes temporary anti-nausea medicines as one option for persistent symptoms. It also describes reassessing the GLP-1 dose. Whether another medicine belongs in the plan is a prescribing decision, rather than an automatic response to this announcement. The broader semaglutide side-effect guide covers the surrounding safety questions.
Both semaglutide labels warn about “Acute Kidney Injury Due to Volume Depletion”: sudden kidney damage linked to lost body fluid. They describe reports of acute kidney injury, in some cases requiring hemodialysis (a machine that filters the blood), mostly in people who became dehydrated from nausea, vomiting, or diarrhea. They call for monitoring kidney function in patients whose side effects could lead to fluid loss, especially when starting or increasing the dose.
Their patient guides call for prompt medical contact for severe or persistent stomach problems. Ongoing vomiting can also have another cause, covered in stomach bugs during GLP-1 treatment. Suppressing vomiting alone would not identify that cause or replace a review of dehydration.
What to watch next
Vanda plans an FDA discussion and a supplemental application, a request to add another use to an existing drug's label. A planned submission is not a decision. Longer studies during gradual semaglutide increases would help answer the practical question: does the added medicine improve tolerability over time?
Semaglutide and tirzepatide prescribed through Promise are dispensed by a licensed U.S. compounding pharmacy as compounded medications, which are different from FDA-approved products: the formulations offered here are not FDA-approved. The FDA explains that it does not verify compounded drugs' safety, effectiveness, or quality before marketing. A licensed provider may still prescribe — that decision is between you and your doctor.
At Promise, a licensed provider reviews every request and not everyone qualifies. A licensed U.S. compounding pharmacy dispenses prescribed medication. New trial results add information to that conversation; they do not make the individual decision.
